<DOC>
	<DOCNO>NCT00006131</DOCNO>
	<brief_summary>OBJECTIVES : I . Compare efficacy safety two dose oral valacyclovir immunocompromised patient uncomplicated herpes zoster . II . Compare quality life , pain , medical resource utilization patient treat 2 regimen .</brief_summary>
	<brief_title>Randomized Study Two Doses Oral Valacyclovir Immunocompromised Patients With Uncomplicated Herpes Zoster</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , double blind study . Patients randomize one two treatment arm . Arm I : Patients receive standard dose oral valacyclovir three time day Days 1-7 . Arm II : Patients receive high dose oral valacyclovir three time day Days 1-7 . Both arm : Patients begin treatment within 72 hour onset zoster rash . Quality life assess Days 1 , 14 , 28 study every 4 week Week 24 . Pain assessed Days 1-28 study , weekly Week 24 . Medical resource utilization assess Days 1 , 8 , 14 , 18 study every 4 week Week 24 . Patients follow every 4 week Week 24 .</detailed_description>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Patients clinical diagnosis uncomplicated herpes zoster present within 72 hour onset zoster rash No evidence cutaneous visceral dissemination herpes zoster infection ; cutaneous dissemination define least 20 discrete lesion outside adjacent dermatome Must immune dysfunction cause following : congenital immune deficiency ; active malignancy type ; collagen vascular disease ; organ bone marrow transplantation ; HIV infection ; severe atopic dermatitis ; receive cytotoxic drug immunosuppressive therapy ( e.g. , chronic systemic corticosteroid ) within past 3 month CD4 count least 50 % Prior/Concurrent Therapy Biologic therapy : Greater 9 month since prior bone marrow transplantation Surgery : Greater 9 month since prior liver heart transplantation Other : At least 4 week since prior topical systemic antivaricella zoster virus ( antiVZV ) medication ; concurrent systemic agent antiVZV activity enrollment Day 10 ; concurrent probenecid 24 hour first dose study drug Day 10 Patient Characteristics Hepatic : AST ALT great 5 time upper limit normal Renal : Creatinine clearance least 30 mL/min Other : Not pregnant nursing ; negative pregnancy test ; fertile patient must use effective contraception ; history intolerance hypersensitivity acyclovir , penciclovir , valacyclovir , famciclovir</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2003</verification_date>
</DOC>